Clinical Observation Of Shugan Xiexin Decoction In The Treatment Of Graves Disease With Heart-Liver Fire Syndrome

1 ObjectiveThis study is to evaluate the effect of Shugan Xiexin Decoction on the clinical symptoms,signs and the indexes before and after treatment in patients with Graves disease with heart-liver fire syndrome,and to explore its effectiveness and safety.2 Methods60 patients with Graves disease of heart-liver fire syndrome were divided into control group and treatment group according to the principle of random control.Both groups were given general treatment,such as rest,avoid iodine diet,high calorie and high nutrition diet.The control group was mainly given methimazole.The treatment group was treated with Shugan Xiexin Decoction for 3 months on the basis of the control group.TCM syndrome scores,TSH,FT3,FT4,TRAb,blood routine,liver function and other safety indicators of two groups were recorded and evaluated before and after treatment.These data were analyzed by SPSS21.0 statistical analysis software.3 ResultsA total of 60 patients were enrolled in this study,30 patients in the control group and 30 patients in the treatment group.There were no cases of abscission or termination during the study.3.1 General informationThere was no significant difference in sex,average age,age distribution,course of disease and degree of illness between the two groups before treatment(Ρ > 0.05).3.2 Therapeutic Indicators 3.2.1 Disease efficacy comparison The difference between the treatment group and the control group was statistically significant after treatment(Ρ < 0.05).3.2.2 Syndrome efficacy comparison The difference between the treatment group and the control group was statistically significant after treatment(Ρ < 0.05).3.2.3 Comparisons of TCM syndromes scores There was no significant difference between the two groups before treatment(Ρ > 0.05),and the two groups were comparable;the two groups were compared before and after treatment,the results showed significant difference(Ρ < 0.05);the two groups were compared after treatment,the results showed significant difference significance(Ρ < 0.01).3.2.4 Comparison of goiter scores There was no significant difference between the two groups before treatment(Ρ > 0.05),the two groups were comparable;the two groups were compared before and after treatment,the results showed significant difference significance(Ρ < 0.01);the two groups were compared after treatment,the results showed significant difference(Ρ < 0.05).3.2.5 Comparison of Graves ophthalmopathy scores There was no significant difference between the two groups before treatment(Ρ > 0.05),the two groups were comparable;the results showed no significant difference between the two groups before and after treatment(Ρ > 0.05).3.2.6 Comparison of thyroid hormone levels There was no significant difference between the two groups before treatment(Ρ > 0.05),the two groups were comparable;the two groups were compared before and after treatment,the results showed significant difference significance(Ρ < 0.01);TSH compared after treatment between the two groups,the results showed significant difference(Ρ < 0.05);FT3 and FT4 compared after treatment between the two groups,the results showed no significant difference(Ρ > 0.05).3.2.7 Comparison of TRAb There was no significant difference between the two groups before treatment(Ρ > 0.05),the two groups were comparable;the two groups were compared before and after treatment,the results showed significant difference significance(Ρ < 0.01);the two groups were compared after treatment,the results showed significant difference(Ρ < 0.05).3.3 Safety indicators 3.3.1 Effects of leukocytes or neutrophils The distribution of leukopenia or neutropenia before treatment was compared between the two groups.The results showed that there was no significant difference between the two groups(Ρ > 0.05),which was comparable;no leukopenia or neutropenia was found in both groups after treatment.3.3.2 Effect on liver function The distribution of abnormal liver function was compared between the two groups before treatment.The results showed that there was no significant difference(Ρ > 0.05),which was comparable.the difference of distribution of abnormal liver function between the two groups after treatment was statistically significant(Ρ < 0.05).3.3.3 rash There was no rash in two groups before treatment,which was comparable.In the treatment,there were 2 patients with skin rash in the control group,but no rash patients in the treatment group.4 ConclusionShugan Xiexin Decoction combined with methimazole can improve TCM symptoms,raise TSH,reduce TRAb level and improve goiter and liver function in Graves disease.Its curative effect is superior to that of methimazole alone.It has high safety and no adverse reactions such as leucopenia,liver damage and rash.It embodies the advantages of TCM.It is confirmed that Shugan Xiexin Decoction combined with methimazole has better therapeutic effect on Graves disease.It provides experience for the treatment of Graves disease and has clinical application value.